Roger Sawhney

Roger A. Sawhney is currently Director at SIRPant Immunotherapeutics, Inc. since 2024, Independent Director at Arbutus Biopharma Corp.
starting 2025, Director at Adlai Nortye Ltd. since 2024, Independent Director at Actuate Therapeutics, Inc. since 2024, and Chief Business Officer at Neuvogen, Inc. Former roles include Director at Alimera Sciences, Inc. in 2023, Managing Director & Partner at The Boston Consulting Group, Inc. from 1996 to 2009, Director at KKR Group Co., Inc. from 2018 to 2020, Independent Director at Arcellx, Inc., Director at New York Institute of Technology, SVP-Corporate Strategy & Business Development at ContextMedia Health LLC from 2017 to 2018, Senior VP & Head-Global Corporate Strategy at Novartis AG from 2009 to 2012, Chief Financial Officer at Stratus Therapeutics, Inc. from 2022 to 2023, Partner at Bain & Co., Inc. from 2012 to 2017, Chief Business Officer at Omega Therapeutics, Inc. in 2022, and Chief Financial Officer at LB Pharmaceuticals, Inc. Education includes undergraduate studies at Stanford University and a doctorate from Harvard Medical School.